...
首页> 外文期刊>Journal of Clinical Microbiology >Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.
【24h】

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.

机译:尖锐湿疣患者的人乳头瘤病毒(HPV)类型分布和对HPV 6型病毒样颗粒的血清学反应。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Thirty-nine patients with condylomas (12 women and 27 men) attending a dermatology clinic were tested for genital human papillomavirus (HPV) DNA and for seroprevalence to HPV type 6 (HPV6) L1 virus-like particles. The L1 consensus PCR system (with primers MY09 and MY11) was used to determine the presence and types of HPV in sample specimens. All 37 (100%) patients with sufficient DNA specimens were positive for HPV DNA, and 35 (94%) had HPV6 DNA detected at the wart site. Three patients (8%) had HPV11 detected at the wart site, and one patient had both HPV6 and -11 detected at the wart site. Thirteen additional HPV types were detected among the patients; the most frequent were HPV54 (8%) and HPV58 (8%). Baculovirus-expressed HPV6 L1 virus-like particles were used in enzyme-linked immunosorbent assays to determine seroprevalence among the patients with warts. Seronegativity was defined by a control group of 21 women who were consistently PCR negative for HPV DNA. Seroprevalence was also determined for reference groups that included cytologically normal women who had detectable DNA from either HPV6 or HPV16 and women with HPV16-associated cervical intraepithelial neoplasia. Among the asymptomatic women with HPV6, only 2 of 9 (22%) were seropositive, compared with 12 of 12 (100%) female patients with warts. A similar trend in increased HPV6 seropositivity with increased grade of disease was found with the HPV16 DNA-positive women, whose seroprevalence increased from 1 in 11 (9%) in cytologically normal women to 6 in 15 (40%) among women with cervical intraepithelial neoplasia 1 or 3. However, only 4 of 25 (16%) male patients were seropositive. No factors examined, such as age, sexual behavior, or a history of warts, were found to definitively account for the gender difference in seroresponse.
机译:对就诊于皮肤科门诊的三名con突患者(12例女性和27例男性)进行了生殖器人类乳头瘤病毒(HPV)DNA的检测,以及对HPV 6型(HPV6)L1病毒样颗粒的血清阳性率。 L1共有PCR系统(带有引物MY09和MY11)用于确定样品中HPV的存在和类型。全部37名(100%)患者具有足够的DNA标本,HPV DNA呈阳性,而35名(94%)患者在疣部位检测到HPV6 DNA。在疣部位检测到HPV11的患者为三名(8%),在疣部位检测到HPV6和-11的患者为一名。在患者中检测到另外13种HPV类型。最常见的是HPV54(8%)和HPV58(8%)。杆状病毒表达的HPV6 L1病毒样颗粒用于酶联免疫吸附测定,以确定疣患者的血清阳性率。血清阴性反应是由21名对HPV DNA始终PCR阴性的女性的对照组定义的。还确定了参考人群的血清阳性率,这些参考人群包括从HPV6或HPV16检测到DNA的细胞学正常女性和患有HPV16相关宫颈上皮内瘤变的女性。在无症状的HPV6妇女中,只有9人中有2人(22%)呈血清反应阳性,而12名女性中有12人(100%)有疣。 HPV16 DNA阳性的妇女发现HPV6血清反应阳性的趋势与疾病等级增加相似,在宫颈上皮内癌患者中,其血清学阳性率从细胞学正常女性的11分之一(9%)增加到15分之6(40%)。瘤形成1或3。但是,在25名男性患者中只有4名(16%)是血清阳性的。没有发现年龄,性行为或疣史等检查因素可以明确说明血清反应的性别差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号